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Although exerting valuable functions in living organisms, nonesteriﬁed fatty acids (NEFAs) can be toxic to cells. Increased blood
concentrationofoleicacid(OLA)andotherfattyacidsisdetectedinmanypathologicalconditions.Insepsisandleptospirosis,high
plasma levels of NEFA and low albumin concentrations are correlated to the disease severity. Surprisingly, 24h after intravenous or
intragastricadministrationofOLA,mainNEFAlevels(OLAinclusive)weredosedependentlydecreased.However,lunginjurywas
detectedinintravenouslytreatedmice,andhighestdosekilledallmice.Whenadministeredbytheenteralroute,OLAwasnottoxic
inanytestedconditions.ResultsindicatethatOLAhasimportantregulatorypropertiesonfattyacidmetabolism,possiblylowering
circulating fatty acid through activation of peroxisome proliferator-activated receptors. The signiﬁcant reduction in blood NEFA
levelsdetectedafterOLAenteraladministrationcancontributetothealreadyknownhealthbeneﬁtsbroughtaboutbyunsaturated-
fatty-acid-enriched diets.
1.Introduction
Nonesteriﬁed fatty acids (NEFAs) are transported by the
blood stream bound to albumin, a condition avoiding their
cytotoxicity [1, 2]. Besides being an important fuel for
the energetic metabolism, they also modulate leukocyte
function, acting as signaling molecules [3–5]. Several cell
types exhibit morphological features of apoptosis and necro-
sis after NEFA exposure [6, 7]. Oleic (OLA) and linoleic
acids activate caspases 3 and 6, enhancing the generation
of reactive oxygen species and a signiﬁcant mitochondrial
depolarization in leukocytes [8, 9].
Symptom severity in diseases as sepsis, leptospirosis, and
pancreatitis is associated to increased serum NEFA [10–
13]. Severe leptospirosis and sepsis are also characterized
by a concomitant decrease in plasma albumin concentration
consequent to a functional liver injury or increased vascular
permeability possibly caused by NEFA toxicity [13–15].
Accordingly, increased OLA and decreased albumin plasma
levels seem to predict the development of acute respiratory
distress syndrome (ARDS) [16, 17]. Since OLA and other
nonesteriﬁedunsaturatedfattyacidsarepotentNa/K-ATPase
inhibitors, whether in vitro [18, 19]o rin vivo [20], the
involvement of the lung Na/K pump inhibition in the advent
of ARDS has to be considered. In experimental animals,
intravenous OLA injection can induce acute lung injury
(ALI) [21, 22]. This syndrome is characterized by neutrophil
inﬁltration and edema formation [23], due to increased
endothelial permeability and loss of epithelial barrier func-
tion [24], causing neutrophil and macrophage accumulation2 Mediators of Inﬂammation
in the lung. Upon activation, these cells produce inﬂam-
matory mediators [25]. Lipid bodies (lipid-rich inclusions
found in the leukocyte cytosol) are also augmented in ALI
[26]. They act as ampliﬁers of inﬂammatory lipid mediator
production such as prostaglandin E2 (PGE2)i nm a c r o p h a g e s
and leukotriene B4 (LTB4) in macrophages and neutrophils
[27]. In the present work, such parameters were used to
characterize the onset of ALI after intravenous oleic acid
administration.
On the other hand, many reports highlight the associ-
ation of unsaturated fatty acid diets to a healthy lifestyle.
The well-known Mediterranean diet contains large amounts
of olive oil, which is rich in the esteriﬁed form of OLA
[28]. Furthermore, dietary monounsaturated fatty acids
were considered protective against metabolic syndrome and
cardiovascular disease risks [29]. Populations using such
diets have reduced serum triglycerides and lower incidence
of cardiovascular problems [30, 31].
The present study aimed at a better understanding of
some deleterious and putative beneﬁcial eﬀects of OLA,
when directly administered to mice. We investigated the con-
sequences of increasing OLA doses, administered by intra-
venousorintragastricroutes,onplasmaNEFAconcentration
and on the triggering of an acute lung injury.
2.MaterialandMethods
2.1. Animals. All experiments were conducted on male Swiss
mice weighting 33 ± 3g obtained from the Oswaldo Cruz
Foundationbreedingunit.Animalswerelodgedat22◦Cwith
a 12h light/dark cycle and free access to food and water.
Animal housing conditions and all experimental procedures
conformed to institutional regulations and were in accor-
dance with the National Institute of Health guidelines on
animal care. All procedures described here were approved
bytheInstitutionalAnimalWelfareCommitteeunderlicense
number 002-08.
2.2. Preparation of Tris-Oleate Solutions. Oleic acid obtained
from Sigma Chemicals was used to prepare a 100mmol/L
tris-oleate solution. After weighting and water addition, tris
powder (Trisma base-Sigma) was slowly added until the pH
reached 10.0. The mixture was sonicated for complete tris-
oleate solubility and then the pH was carefully adjusted to
7.6withdilutedHCl.Workingoleatesolutionswereprepared
by appropriate dilutions of the 100mmol/L solution with
phosphate buﬀered saline (PBS) pH 7.6.
2.3. Intravenous Administration of Oleate. Intravenous injec-
tions were performed into the orbital plexus (inner angle of
the eye ball), and blood was collected by cardiac puncture
24h latter. In some experiments, blood samples were col-
lected6 afterthe injection. Control groups received 100μLo f
saline. Other groups received 100μL of tris-oleate solutions
corresponding to oleate doses of 20, 40, 80, and 160mg/kg.
2.4. Intragastric Administration of Oleate. A thin catheter
coupled to a 1.0mL syringe was introduced through the
mouse esophagus and 100μL of the appropriate oleate
solution or PBS (control animals) were injected into the
gastriclumen.Oleatedoses of20,40, 80,and160mg/kgwere
alsoused.Bloodwascollectedbycardiacpuncture24hlatter.
2.5. Plasma NEFA Quantiﬁcation. Plasma concentrations of
the predominant NEFA—palmitic, oleic, linoleic, palmi-
toleic, and stearic acids—were determined by high per-
formance liquid chromatography (HPLC) as described by
Puttman et al. [32]. Methodological details were delineated
in a previous publication [13].
2.6. Albumin Quantiﬁcation. Plasma albumin concentration
was determined by the colorimetric procedure of Doumas et
al. [33] using bovine serum albumin solutions as standards.
2.7. Total and Diﬀerential Cell Analysis on Bronchoalveolar
Lavage Fluid (BALF). The bronchoalveolar lavage was per-
formed after isolating the trachea by blunt dissection. A
small caliber tube was inserted and secured in the airway.
PBS (1.0mL) was then instilled and gently aspirated. This
procedure was repeated three times, and collected ﬂuids
were pooled. In every instillation/aspiration cycle, the same
volume (1.0mL) was recovered from each animal. Total
leukocyte counts were performed by light microscopy in
Neubauer chambers after diluting BALF samples in T¨ urk’s
solution (2% acetic acid). Diﬀerential leukocyte counts were
determined in cytocentrifuged smears stained by the May-
Grunwald-Giemsa method. Total BALF protein was deter-
mined by the Micron BCA Kit method (Pierce) according to
the manufacturer’s instructions.
2.8. Lipid Body Staining and Counting. While still moist,
leukocytes on cytospin slides were ﬁxed in 3.7% formalde-
hyde in Ca2+,M g 2+-free Hank’s balanced salt solution
(HBSS), pH 7.4 and stained with 1.5% OsO4 as described
in Bozza et al. [34]. Lipid bodies were counted by light
microscopy with oil immersion objective lens in 50 consecu-
tively scanned leukocytes.
2.9. PGE2 and LTB4 Assays. LTB4 and PGE2 in BALF
supernatants were assayed by ELISA kits according to the
manufacturer’s instructions (Cayman Chemical, Ann Arbor,
MI).
2.10. Statistical Analysis. Results were expressed as mean ±
SEM and were analyzed by the Neuman-Keuls-Student test.
Diﬀerences were considered signiﬁcant when P<0.05.
3. Results
When mice were intravenously injected with increasing OLA
doses (20, 40 and 80mg/kg), a dose-dependent decrease
in plasma NEFA concentrations especially oleic, linoleic
and palmitic acids (Figure 1(a)), and total fatty acids
(Figure 1(b))wereobserved24haftertheinjection.Todeﬁne
if this eﬀect could be detected at an earlier moment, weMediators of Inﬂammation 3
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Figure 1: Plasma NEFA concentrations in mice after intravenous OLA injections. (a) Plasma concentrations of palmitoleic, linoleic,
palmitic, oleic, and stearic acids 24h after 20, 40, and 80mg/kg oleic acid doses (mean ± SEM of 5 diﬀerent experiments). (b) Total
NEFA concentration (sum of average concentrations of the ﬁve NEFA). All mice receiving the 160mg/kg dose died 10–20 minutes after
the intravenous injection and could not be computed. (c) Plasma concentrations of palmitoleic, linoleic, palmitic, oleic, and stearic acids 6h
after the injection of the 80mg/kg oleic acid dose (mean ± SEM of 4 independent experiments). ∗P<0.05 (versus controls).
Table 1: Plasma albumin concentrations 24h after intravenous (I.V.) and intragastric (I.G.) OLA administration.
OLA dose (mg/kg)
Controls 20 40 80 160
Albumin (μM) I.V. OLA 357.2 ±8.1 338.6 ±8.8 325±20.0 301.6 ±18.2n d
Albumin (μM) I.G. OLA 367.3±12.1 333.3 ±9.6 326.4 ±19.1 319.0 ±34.1 350.1 ±19.4
Nd: not determined.
Results are mean ± SEM of 6 to 7 diﬀerent experiments.
performed an experiment evaluating NEFA concentrations
6h after OLA injection, using the 80mg/kg OLA dose (this
dose corresponded to the maximal response obtained in
the experiment of Figure 1(a)). Results for this early-time
point (Figure 1(c)) showed only minor decreases relative
to controls in some NEFA concentrations which were not
statistically signiﬁcant. Albumin levels were only slightly
altered (Table 1).
In order to characterize the onset of ALI, we mea-
sured in BALF samples the following parameters: protein
extravasation, leukocyte accumulation, lipid body formation
in leukocytes and PGE2 and LTB4 production, which were4 Mediators of Inﬂammation
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Figure 2: Leukocyte migration, protein extravasation, and LTB4 production in BALF after intravenous OLA injections. Mononuclear cells,
neutrophils, and total protein (in BALF supernatants) were measured 24h after injections, while LTB4 was assayed in supernatants 6h after
injections. Results represent the mean ± SEM of 3 independent experiments. ∗P<0.05.
used as markers of lung edema and inﬂammation. Although
OLA is potentially able to induce lung injury, intravenously
injected OLA in 20 and 40mg/kg doses did not induce
BALF cell migration or did not produce modiﬁcations on
proteinBALFcontent(Figure 2).Notwithstanding,24hafter
the 80mg/kg dose, an inﬁltration of mononuclear cells and
neutrophils, as well as an augmented total BALF protein,
was detected. LTB4 was also signiﬁcantly increased 6h after
this challenge (Figure 2). Lipid bodies in BALF leukocytes
and the lipid mediator PGE2 in BALF supernatant (Figure 3)
were also considerably augmented 24h after this same OLA
challenge. A dose of 160mg/kg killed all mice. These animals
presented early signs of severe lung injury and died within 10
minutes after injections.
When the same OLA doses were administered to mice
by the enteral route, lowered individual and total NEFA
concentrations were also detected (Figures 4(a) and 4(b),
resp.). This decrease was substantially more pronounced
than the one seen in intravenously treated animals. Lung
injury was not found even in the highest dose tested as
c a nb es e e ni nFigure 5. Since lung edema and leukocyte
inﬁltration were not detected in this experiment, assays for
inﬂammatory mediators were not performed.
4. Discussion
Herein we demonstrated an unexpected decrease in NEFA
plasma levels after intravenous or enteral OLA adminis-
tration. In this regard, several studies have shown that
fatty acids can regulate its own metabolism, acting at
gene transcription level. Some transcription factors are
prospective fatty acid targets regulating the expression of
enzymesinvolvedinlipidmetabolism[35–38].Nonesteriﬁed
fatty acid availability is sensed by peroxisome proliferator-
activated receptors (PPARs), which are nuclear receptors
controlling fatty acid storage, degradation, and adipocyte
diﬀerentiation [39, 40]. Although in the present study we
did not test OLA binding to PPAR, this fatty acid was
already reported so eﬀective as polyunsaturated fatty acidsMediators of Inﬂammation 5
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Figure 3: Lipid body formation and prostaglandin production in BALF after intravenous OLA injections. BALF were collected 24h after
injectionsofthe80mg/kgdose.Eachbarrepresentsthemean ±SEMoflipidbodiespercellin50consecutivelycountedcellsfrom6diﬀerent
animals. PGE2 quantiﬁcation is the mean ± SEM of 3 independent experiments. ∗P<0.05.
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Figure 4: Plasma NEFA concentrations after OLA administration by the gastric route. (a) Plasma concentrations of palmitoleic, linoleic,
palmitic, oleic, and stearic acids 24h after 20, 40, 80, and 160mg/kg oleic acid doses; (b) total NEFA concentration (sum of average
concentrations of the ﬁve NEFA). Results represent data from 5 independent experiments (mean ± SEM). ∗P<0.05.
in PPARα binding and activation [41] and was also a PPARγ
ligand [42]. In fact, PPARα activation in the liver stimulates
the transcription of carnitine palmitoil-transferase 1 (CPT1)
and uncoupling protein 1, leading to increased fatty acid
degradation [43]. Fish oils contain PPARα activators that,
similarly to hypolipidemic drugs, decreased triglyceride
synthesis and increased mitochondrial fatty acid β-oxidation
[44]. PPARγ activation augmented fatty acid clearance by
the adipose tissue and hepatocytes, consequently decreasing
their plasma concentrations [45]. Hence, PPAR activation
seems to be an important condition decreasing nonesteriﬁed
fatty acid blood concentrations. In this way, PPARγ agonists
lowered plasmatic NEFA concentration [45] while PPARα
agonists led to a similar eﬀect by increasing NEFA oxidation
[46].
Mice receiving OLA through the intravenous route
(80mg/kg) already presented signals of lung injury, char-
acterized by increased protein extravasation, cell migration
and cell activation with increased lipid body formation
and PGE2 release. Moreover, LTB4, a potent neutrophil
chemotactic molecule [47], was augmented at an early
stage, thus contributing for neutrophil migration. In our
conditions, OLA lung toxicity can be explained by the
rapid arrival of albumin unbound-OLA in the lung capillary
net. It is important to note that this amount of OLA, if
diluted in the whole mouse blood (considered as 2.5mL),
would give a concentration of at least 4000μmol/L, which
is around 1.7 and 6.6 times the control levels of total
fatty acid and OLA, respectively. Surely, during the few
seconds of traveling from the injection point to lung, OLA
concentration would be much higher than 4000μmol/L.6 Mediators of Inﬂammation
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Figure 5:LeukocytemigrationandproteinextravasationinBALFafterOLAadministrationbythegastricroute.Bronchoalveolarﬂuidswere
collected 24h after OLA administration. Total cells, mononuclear cells, and neutrophils were counted. Total protein in BALF supernatants
was also assayed. Results represent the mean ± SEM of 3 independent experiments.
Moreover, a 160mg/kg intravenous dose killed all animals
within 10min after injections, a toxic eﬀect certainly due
to albumin unbound-OLA. In this context, it was pro-
posed that the toxicity of intravenously administered OLA
could be diminished by a concomitant albumin injection
[48].
OLA enteral administration was not toxic in any tested
doses. Since an appreciable part of OLA undergoes ester-
iﬁcation during the intestinal absorptive mechanism and
considering that intestinal absorption is a much slower
process, an increase in albumin unbound-OLA is prevented
inthiscondition.ItisworthofnotethatOLAadministration
by the gastric route (40–80mg/kg) was twice as much
eﬃcient in lowering total plasma NEFA (a decrease of
about 60%) than the intravenous administration (around
30%). At this point, we would like to emphasize published
data showing that mice consuming olive oil-enriched diet
(thus an OLA enriched-diet) had increased survival after
a LPS induced-shock [49]. This shock is characteristically
seen in sepsis, a disease coursing with high plasma NEFA
concentrations. In this case, diet-induced-reduced-plasma
NEFA could be an explanation for the extended mice sur-
vival.
There are evident diﬀerences in OLA distribution in
the body when this fatty acid is administered by intra-
venous or enteral routes. In intravenously treated animals,
OLA is rapidly and signiﬁcantly trapped in the lung
microvasculature causing lung inﬂammation. After enteral
administration, OLA is mostly esteriﬁed and transported
through the abdominal lymphatic system then reaching the
venous system, heart, lung and, afterwards, is distributed
to the whole organism. The enteral route follows, thus,
the normal physiologic mechanisms of lipid absorption and
transport.
Other nonesteriﬁed fatty acids may have similar eﬀects
on NEFA plasma levels. In this work, OLA was chosen
because not only toxic but also beneﬁc eﬀects of this fatty
acid are well documented in the literature.Mediators of Inﬂammation 7
5. Conclusions
In conclusion, OLA seems to participate in the regulation
of fatty acid metabolism. Intravenous OLA administration
(40mgperkgofbodyweight)loweredplasmaNEFAconcen-
trations, but higher doses were toxic, leading to lung injury
or killing the animals. On the other side, our results suggest
ab e n e ﬁ ce ﬀect of low doses of orally administered OLA
(about40to80mgperkgofbodyweight)inreducingplasma
NEFA concentrations of normal animals. This ﬁnding sum
up the other beneﬁts brought about by the ingestion of diets
containing OLA-enriched fat, particularly olive oil.
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